Shares of Adaptive Biotechnologies Corp. (ADPT) are up over 10% at $17 in premarket trading on Monday, following preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025.
The company operates through two primary businesses: the Minimal Residual Disease (MRD) business and the Immune Medicine (IM) business.
The MRD business centers around its flagship clonoSEQ diagnostic test, which is FDA-authorized for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia. Additionally, clonoSEQ is available as a CLIA-validated laboratory-developed test for other lymphoid cancers, including diffuse large B-cell lymphoma and mantle cell lymphoma. The IM business is focused on the discovery and development of immune-based therapies for cancer and autoimmune diseases.
For the fourth quarter of 2025, total revenue was $72 million, with MRD revenue accounting for approximately $62 million. This compares with total revenue of $47.5 million and MRD revenue of $40.1 million in Q4, 2024.
For the full year of 2025, total revenue was approximately $277 million, with MRD revenue contributing $212 million. This represents growth from total revenue of $179.0 million, including MRD revenue of $145.5 million in 2024.
ClonoSEQ test volume was 30,000 tests in Q4 2025, a 43% increase compared to Q4 2024. For the full year 2025, approximately 105,600 tests were delivered, representing a 39% increase over 2024.
Adaptive Biotechnologies plans to release its complete fourth quarter and full year 2025 financial results in February 2026.
ADPT closed Friday's trading at $15.76, down 1.25%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.